Latest News — Page 8

How will Portugal’s new pricing framework reshape dapagliflozin access and reimbursement? 📊💊

This article unpacks the framework’s key levers—value-based agreements, volume discounts and reference pricing—and explains how they may speed up market access while managing payer budgets. It also highlights practical implications for manufacturers, payers and patient access across Portugal.

Read the full analysis for actionable takeaways and next steps.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Who should drive oncology market access — and how do you align them to speed patient access? 🤝🎯

This article lays out a practical multistakeholder strategy for oncology market access, emphasizing early payer and HTA engagement, real‑world evidence, patient‑centred value frameworks, and coordinated pricing and reimbursement approaches to balance innovation with system sustainability.

Read the full piece to get actionable steps and real-world examples for aligning industry, payers, clinicians, and patients.

#SyenzaNews #oncology #HealthEconomics #MarketAccess #healthcarepolicy

Can AI + real-world evidence transform how medicines are regulated?

Regulators are increasingly leveraging RWE and AI to speed approvals, strengthen post‑market surveillance, and enable more patient‑centered decisions — but success depends on data quality, transparent algorithms, and cross‑sector collaboration. This article outlines emerging frameworks, key risks to manage, and practical steps for regulators, industry, and tech partners.

Read the full piece to see how stakeholders can responsibly scale RWE and AI in medicines regulation. 🔍

#SyenzaNews #regulatoryaffairs #AIinHealthcare #ai #healthcarepolicy

Medicine shortages putting patient care at risk? 💊📈

Supply-chain disruptions, regulatory constraints, and manufacturing bottlenecks are creating persistent drug gaps — but coordinated forecasting, supplier diversification, digital tracking, and policy levers can restore resilience and equitable access. This article outlines practical management strategies and policy recommendations to improve medicine availability and reduce stockouts.

Read the full piece to explore actionable solutions for health systems and industry stakeholders.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Who is accountable when an AI-driven clinical decision causes harm? 🤖⚖️

This article breaks down legal liability, ethical responsibilities, and practical governance for AI in clinical practice, highlighting where responsibility lies between clinicians, vendors, and health systems and how robust oversight can protect patients.

Read the full piece to learn concrete steps for hospitals, regulators, and clinicians to manage AI risk and ensure safe, accountable deployment.

#SyenzaNews #AIinHealthcare #HealthTech #healthcarepolicy #governance

Could expanded regulatory approval for OTC glucose monitors bring safer, easier diabetes management for children? 🩺

Regulators are widening pathways for over‑the‑counter pediatric glucose monitoring—promising improved access, greater caregiver autonomy, and new safety and labeling expectations that manufacturers and clinicians must navigate. The change also reshapes market access and commercial strategy for MedTech players.

Read the full article to understand the regulatory details, clinical implications, and what stakeholders should do next.

#SyenzaNews #medicaldevices #regulatoryaffairs #healthcarepolicy #MarketAccess

Could certain low‑risk medical products now skip FDA premarket review — and what does that mean for medtech teams?

This article explains FDA exemption pathways for low‑risk, unclassified devices, how qualifying products can reach market faster, and the compliance obligations (registration, labeling, reporting) manufacturers must still meet.

Read the full piece to learn which devices may qualify, practical steps to leverage exemptions, and common pitfalls to avoid. 🚀

#SyenzaNews #medicaldevices #regulatoryaffairs #MarketAccess #healthcarepolicy

Struggling to turn medtech innovation into reimbursable care? 💡📈

This article lays out practical reimbursement strategies — from early payer engagement, HTA-aligned evidence generation and real‑world data to coding, value‑based pricing, and payer partnerships — to accelerate market access and sustainable adoption.

Read the full piece for a step‑by‑step playbook and real‑world examples to de‑risk your commercialization plan.

#SyenzaNews #MedTech #HealthEconomics #MarketAccess #healthcarepolicy

Can a unified pharmaceutical-access initiative finally ensure timely, affordable medicines across Europe? 💊

The plan centers on coordinated HTA, pooled procurement, shared data and pricing transparency to streamline market access, lower costs and reduce cross-country disparities. Its success will depend on strong governance, sustainable funding and political commitment.

Read the full article to see the recommended roadmap, stakeholder impacts and next steps for implementation.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

How should regulators prioritize AI research across the medicines lifecycle? 🤖

This piece summarizes the top research priorities — from transparency and evidence standards for trials and real-world data to post-market surveillance, risk governance, and cross-sector collaboration — to safely and effectively integrate AI into drug development and regulation.

Read the full article to see the recommended research agenda and practical steps for regulators, industry, and researchers.

#SyenzaNews #regulatoryaffairs #AIinHealthcare #ai #healthcarepolicy

Could strengthening health systems be the missing link to economic security and growth across CEE? 📈🌍

This piece highlights how targeted health investments, smarter resource allocation, and policy reforms can boost economic resilience in Central and Eastern Europe—identifying cost‑effective interventions and governance levers that policymakers and investors should watch.

Read the full article for practical recommendations and opportunities to support sustainable regional growth.

#SyenzaNews #HealthEconomics #HealthcareInnovation #economicanalysis #healthcarepolicy

Can gene therapy restore sight — and still fit into healthcare budgets? 👁️

This piece unpacks reimbursement pathways for vision-restoring gene therapies (e.g., RPE65/Luxturna), highlighting value assessment, long-term evidence needs, and practical payment models like outcomes-based agreements and annuities to manage uncertainty and budget impact.

Read the full article to explore pragmatic strategies that payers, manufacturers, and clinicians can use to secure sustainable patient access.

#SyenzaNews #biotechnology #HealthEconomics #MarketAccess #healthcarepolicy

Could delpacibart and braxlosiran be the disease‑modifying breakthrough FSHD patients have been waiting for? 🧬🔬

Early clinical data suggest both programs use distinct, targeted approaches to tackle the underlying biology of FSHD, offering real potential to slow or stop progression — and redefining what’s possible for patients, developers and payers.

Read the full piece to understand the science, trial readouts, and what the next steps mean for access and adoption.

#SyenzaNews #biotechnology #clinicaltrials #innovation #healthcarepolicy

Can predictive analytics keep athletes healthier and competing longer? 🏃‍♀️📊

This piece outlines how risk‑stratification frameworks—combining wearables, workload metrics, biomarkers and machine learning—can identify athletes at elevated injury risk and enable targeted interventions that reduce downtime and improve performance. It also highlights practical implementation steps and real-world case examples.

Read the full article to learn the frameworks, tools, and next steps for putting predictive risk management into practice.

#SyenzaNews #AIinHealthcare #HealthTech #datascience #innovation

Are Portugal’s HTA delays putting patient access to innovative therapies on hold? ⏳

Delays to HTA reform are creating reimbursement bottlenecks and uncertainty for manufacturers, slowing adoption of breakthrough treatments and increasing reliance on short‑term, ad hoc access schemes. The article outlines the consequences for patients and providers and recommends clearer timelines, real‑world evidence use, and managed‑entry agreements to restore timely access.

Read the full analysis to understand the policy impacts and practical steps for quicker access.

#SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

Are Dutch patients waiting too long for new medicines? ⏳

This article examines how prolonged HTA reviews, pricing negotiations and fragmented reimbursement pathways are delaying access to innovative therapies and affecting patient outcomes. It also offers practical fixes — earlier stakeholder dialogue, streamlined assessment timelines and managed-entry agreements — to accelerate access without sacrificing value.

Read the full article for case studies and actionable policy recommendations.

#SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy